Spero Therapeutics (SPRO) Income towards Parent Company (2016 - 2026)

Spero Therapeutics (SPRO) has 11 years of Income towards Parent Company data on file, last reported at -$7.4 million in Q1 2026.

• Quarterly Income towards Parent Company rose 46.75% year-over-year to -$7.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$113.5 million (up 40.58% YoY) and the FY2025 annual result came in at $5.2 million, up 102.71% from the prior year.
• Income towards Parent Company slipped to -$7.4 million in Q1 2026, from $29.3 million in the prior quarter.
• In the past five years, Income towards Parent Company ranged from a high of $29.3 million in Q4 2025 to a low of -$142.7 million in Q4 2024.
• A 5-year average of -$33.5 million and a median of -$16.5 million in 2024 frame the typical range for Income towards Parent Company.
• The widest YoY moves for Income towards Parent Company: up 120.55% in 2025, down 502.72% in 2025.
• Tracing SPRO's Income towards Parent Company over 5 years: stood at -$92.4 million in 2022, then jumped by 35.51% to -$59.6 million in 2023, then tumbled by 139.5% to -$142.7 million in 2024, then soared by 120.55% to $29.3 million in 2025, then sank by 125.19% to -$7.4 million in 2026.
• The last three Income towards Parent Company figures came in at -$7.4 million (Q1 2026), $29.3 million (Q4 2025), and -$27.7 million (Q3 2025), per Business Quant data.